// App-Quantinova.ai

M2052 2016 AHA : Alirocumab Dosing in a Real World Setting: Data From an Open-label Treatment Extension to the ODYSSEY Program for Patients With Heterozygous Familial Hypercholesterolemia

Researchers

Presenter

  • John R Guyton

Principal Investigators

  • Gisle Langslet

  • Robert Dufour

  • Marie T Baccara-Dinet

  • Chantal Din-Bell

  • Garen Manvelian

  • Michel A Farnier

Medical Centers

  • Academic Medical Center, Amsterdam, Netherlands

  • Duke Hosp, Durham, NC

  • Oslo Univ Hosp, N- Oslo, Norway

  • University of Montreal, Montreal, QC, Canada

  • Point Medical, Dijon, France

Locations

  • Canada

  • Norway

  • Netherlands

  • United States

  • France

Companies

  • Regeneron Pharmaceut

  • Sanofi S.A.

Study Components

Therapeutic Area

  • Genetic Disorder

  • Endocrine/metabolic Diseases (ME)

Disease

  • Hypercholesterolemia, Familial, 1

  • Hyperaldosteronism, familial, 2

  • Glucocorticoid remediable aldosteronism

Biomarkers

  • N/A

Drug/Treatment

  • Alirocumab

Outcome

  • N/A

Study Design

  • open label

  • double blind/blinded

Phase

  • III

Study Id's

  • NCT01954394

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved